EGFR and head and neck squamous cell carcinoma: Our data suggests that osimertinib could be efficacious in HNSCC expressing high levels of EGFR ligands, with low expression of members of the TGF-beta pathway, and clinical trial designs that examine and validate these biomarkers is warranted.